Financials in USD. Standardized financial statements.
A compact view of how Phathom Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $175.11M | $55.25M | $682,000 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +216.9% | +8001.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $22.60M | $7.97M | $167,000 | $620,000 | $521,000 | $300,000 | $8,000 | $0 |
| Gross Profit? | $152.51M | $47.28M | $515,000 | -$620,000 | -$521,000 | -$300,000 | -$8,000 | $0 |
| Gross Margin? | +87.1% | +85.6% | +75.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $312.50M | $324.75M | $167.83M | $171.82M | $134.56M | $125.36M | $106.22M | $1.23M |
| Operating Income? | -$159.99M | -$277.47M | -$167.31M | -$172.44M | -$135.08M | -$125.67M | -$106.22M | -$1.23M |
| EBITDA? | -$159.35M | -$261.52M | -$159.05M | -$169.80M | -$136.57M | -$124.19M | -$250.95M | -$50,000 |
| Income Before Tax | -$221.25M | -$334.33M | -$201.59M | -$197.72M | -$143.88M | -$129.07M | -$255.13M | -$1.29M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $13,000 |
| Net Income? | -$221.25M | -$334.33M | -$201.59M | -$197.72M | -$143.88M | -$129.07M | -$209.74M | -$1.29M |
| EPS? | $-3.03 | $-5.29 | $-3.93 | $-5.70 | $-4.00 | $-4.01 | $-8.48 | $-0.15 |
| Diluted EPS? | $-3.03 | $-5.29 | $-3.93 | $-5.70 | $-4.00 | $-4.01 | $-8.48 | $-0.15 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality